ASP1235 (AGS62P1)

· Astellas Pharma Global Development, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ASP1235 (AGS62P1), covering 2024-10-23 to 2024-10-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]

See pricing